Vellenga E - Search Results

1

Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.

van der Graaf WT, de Vries EG, Timmer-Bosscha H, Meersma GJ, Mesander G, Vellenga E, Mulder NH. van der Graaf WT, et al. Among authors: vellenga e. Cancer Res. 1994 Oct 15;54(20):5368-73. Cancer Res. 1994. PMID: 7923167

2

Effect of ultrafilterable platinum concentration on cisplatin and carboplatin cytotoxicity in human tumor and bone marrow cells in vitro.

Guchelaar HJ, de Vries EG, Meijer C, Esselink MT, Vellenga E, Uges DR, Mulder NH. Guchelaar HJ, et al. Among authors: vellenga e. Pharm Res. 1994 Sep;11(9):1265-9. doi: 10.1023/a:1018934209719. Pharm Res. 1994. PMID: 7816754

3

The combined effects of IL-3 and PSC 833 on daunorubicin- and mitoxantrone cytotoxicity in two growth factor-dependent leukemic cell lines.

Asschert J, de Vries E, van der Kolk D, Müller M, Vellenga E. Asschert J, et al. Among authors: vellenga e. Leukemia. 1997 May;11(5):680-6. doi: 10.1038/sj.leu.2400639. Leukemia. 1997. PMID: 9180292

4

Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells.

van der Kolk DM, de Vries EG, Koning JA, van den Berg E, Müller M, Vellenga E. van der Kolk DM, et al. Among authors: vellenga e. Clin Cancer Res. 1998 Jul;4(7):1727-36. Clin Cancer Res. 1998. PMID: 9676848

5

P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.

van der Kolk DM, de Vries EG, van Putten WJ, Verdonck LF, Ossenkoppele GJ, Verhoef GE, Vellenga E. van der Kolk DM, et al. Among authors: vellenga e. Clin Cancer Res. 2000 Aug;6(8):3205-14. Clin Cancer Res. 2000. PMID: 10955805

6

In vitro and in vivo modulation of multi-drug resistance with amiodarone.

van der Graaf WT, de Vries EG, Uges DR, Nanninga AG, Meijer C, Vellenga E, Mulder PO, Mulder NH. van der Graaf WT, et al. Among authors: vellenga e. Int J Cancer. 1991 Jun 19;48(4):616-22. doi: 10.1002/ijc.2910480422. Int J Cancer. 1991. PMID: 1646180

7

The effects of five hematopoietic growth factors on human small cell lung carcinoma cell lines: interleukin 3 enhances the proliferation in one of the eleven cell lines.

Vellenga E, Biesma B, Meyer C, Wagteveld L, Esselink M, de Vries EG. Vellenga E, et al. Cancer Res. 1991 Jan 1;51(1):73-6. Cancer Res. 1991. PMID: 1703041

8

A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.

de Vries EG, Biesma B, Willemse PH, Mulder NH, Stern AC, Aalders JG, Vellenga E. de Vries EG, et al. Among authors: vellenga e. Cancer Res. 1991 Jan 1;51(1):116-22. Cancer Res. 1991. PMID: 1988077 Clinical Trial.

9

Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients.

Nieken J, Mulder NH, Buter J, Vellenga E, Limburg PC, Piers DA, de Vries EG. Nieken J, et al. Among authors: vellenga e. Blood. 1995 Aug 1;86(3):900-5. Blood. 1995. PMID: 7542502 Free article. Clinical Trial.

10

VP-16-mediated cytotoxicity is modulated by interleukin-3 in a growth factor-dependent leukemic cell line.

Vellenga E, Asschert L, Withoff S, van der Kolk D, de Vries EG. Vellenga E, et al. Leukemia. 1994 Dec;8(12):2060-4. Leukemia. 1994. PMID: 7807995

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

498 results

Search Page

Filters